1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Austria >
  5. Oncomatryx Acquires Tube

M&A Deal Summary

Oncomatryx Acquires Tube

On May 18, 2023, Oncomatryx acquired life science company Tube

Acquisition Highlights
  • This is Oncomatryx’s 1st transaction in the Life Science sector.
  • This is Oncomatryx’s 1st transaction in Austria.

M&A Deal Summary
Date 2023-05-18
Target Tube
Sector Life Science
Buyer(s) Oncomatryx
Deal Type Add-on Acquisition

Target

Tube

Vienna, Austria
Tube is a developer of the Cytolysin toxic payload using core assets that are natural product classes and their synthetic analogs comprising a product platform with multiple partnering and development opportunities. The compound classes show an extremely potent biological activity profile against tubulin and are predominantly useful for novel therapeutic approaches in oncology. Tube is based in Vienna, Austria.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Oncomatryx

Derio, Spain
Category Company
Sector Life Science
DESCRIPTION

Oncomatryx is a global biopharmaceutical company that targets the microenvironment of the most invasive tumors through its precision ADCs, bispecific antibodies, and small molecules. The company has discovered novel mechanisms and proteins in the tumor microenvironment that facilitate tumor invasiveness, immunosuppression, drug resistance, and metastasis. Oncomatryx is based in Derio, Spain.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Austria M&A 1 of 1
Year: 2023 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal